Suchergebnisse - "Lebwohl, Mark G"

PubPharm (319)

1

Generalized pustular psoriasis : A consensus statement from the National Psoriasis Foundation

enthalten in: Journal of the American Academy of Dermatology | 2024

von Armstrong, A. | Elston, C. | Elewski, B. | +32

2

Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis

enthalten in: The British journal of dermatology | 2024

von Guénin, S. | Andrews, E. | Lebwohl, M.

3

Nail psoriasis and nail lichen planus : Updates on diagnosis and management

enthalten in: Journal of the American Academy of Dermatology | 2024

von Hwang, J. | Grover, C. | Iorizzo, M. | +4

4

Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Burden, A. | Bissonnette, R. | Anatchkova, M. | +8

5

Sarecycline as a Potential Treatment for Steroid-Induced Rosacea/Perioral Dermatitis : A Case Report

enthalten in: Journal of drugs in dermatology : JDD | 2024

von Sher, A. | Kresch, M. | Bitterman, D. | +2

6

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis : 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2024

von Papp, K. | Lebwohl, M. | Thaçi, D. | +20

7

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease : An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

enthalten in: Drug safety | 2024

von Strober, B. | Coates, L. | Lebwohl, M. | +13

8

Post-Hyaluronic Acid Filler Reaction Treated With Abrocitinib : A Case Report

enthalten in: Journal of drugs in dermatology : JDD | 2024

von Lopez, M. | Guenin, S. | Laborada, J. | +1

9

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis : Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

enthalten in: Journal of the American Academy of Dermatology | 2023

von Papp, K. | Blauvelt, A. | Puig, L. | +14

10

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

enthalten in: BioDrugs | 2023

von Papp, K. | Lebwohl, M. | Thaçi, D. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[32]